Antisense oligonucleotide inhibitors of isozymes of protein kinase C: in vitro and in vivo activity, and clinical development as anti-cancer therapeutics.

K McGraw(Ionis Pharmaceuticals (United States)), Dean Nm, Loren Miraglia(Genomics Institute of the Novartis Research Foundation), Boggs Rt, Robert A. McKay(Ionis Pharmaceuticals (United States)), Pribble Jp, Thomas Geiger(Novartis (Switzerland)), Marcel A. Müller(University of Bonn), Doriano Fabbro(Novartis (Switzerland))
PubMed
July 1, 1997
Cited by 22

Related Papers

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
|Nature|2013|2.1k
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting
|Cell Metabolism|2006|2.1k
The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY
|Nucleic Acids Research|2017|1.7k
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
|Nature|2020|1.4k
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent <i>in vivo</i> antitumor activity
|Molecular Cancer Therapeutics|2008|1.1k